TIDMODX

RNS Number : 0627A

Omega Diagnostics Group PLC

31 January 2022

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014. Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain.

OMEGA DIAGNOSTICS GROUP PLC

("Omega" or the "Company" or the "Group")

Speculation regarding a potential fundraise

Omega (AIM: ODX), the specialist medical diagnostics company focused on industry-leading Global Health (CD4 and COVID-19) and Health and Nutrition products , notes the recent online speculation and confirms that it is in discussions with certain investors and shareholders regarding a potential equity fundraising.

Market conditions remain challenging and accordingly any issue of equity would be at a discount to the current share price. Any fundraise would include an open offer to accommodate retail investors.

As per the announcement of 19 January, the Company has significant cash resources . Accordingly, there is no immediate need to raise additional capital and the Company may choose not to proceed with a fundraising until such time as conditions are more favourable.

A further announcement will be made in due course as necessary.

Contacts:

 
  Omega Diagnostics Group PLC                                                          www.omegadx.com 
  Jag Grewal, Chief Executive Officer                                                  via Walbrook PR 
  Chris Lea, Chief Financial Officer 
 
  finnCap Ltd                                                                       Tel: 020 7220 0500 
  Geoff Nash/Edward Whiley/George Dollemore (Corporate 
   Finance) 
  Alice Lane/ Charlotte Sutcliffe (ECM) 
 
  Walbrook PR Limited                                       Tel: 020 7933 8780 or omega@walbrookpr.com 
  Paul McManus                                                                      Mob: 07980 541 893 
  Lianne Applegarth                                                                 Mob: 07584 391 303 
  Sam Allen                                                                         Mob: 07502 558 258

About Omega Diagnostics Group PLC

Omega manufactures and distributes high quality in-vitro diagnostic products for use in hospitals, clinics, laboratories and healthcare practitioners in over 75 countries and specialise in the areas of health and nutrition and global health.

www.omegadx.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

MSCSDEESSEESEDF

(END) Dow Jones Newswires

January 31, 2022 01:59 ET (06:59 GMT)

Omega Diagnostics (LSE:ODX)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024 Haga Click aquí para más Gráficas Omega Diagnostics.
Omega Diagnostics (LSE:ODX)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024 Haga Click aquí para más Gráficas Omega Diagnostics.